Reckitt Benckiser outbids rivals with Rs3,263 crore bid for Paras Pharmaceuticals
13 Dec 2010
Reckitt Benckiser plc, the world's largest producer of household products and a major producer of consumer healthcare and personal products company yesterday outbid other big pharma majors in the race for Ahmedabad-based Paras Pharmaceuticals.
In 1999, Reckitt & Colman and Benckiser merged to become Reckitt Benckiser.
The Slough, UK-based company yesterday revealed that it will acquire Paras for Rs3,263 crore ($726 million).
Private equity firms, Actis Capital LLP that invests in emerging markets holding 62 per cent of closely-held Paras, Sequoia Capital, one of Google Inc and Yahoo! Inc's early investors, owning about 8 per cent and Paras chairman Girish Patel and employees holding the remaining interest will sell their stake to Reckitt Benckiser.
The announcement of the deal will be a blow to GlaxoSmithkline, Sanofi-Aventis, Johnson & Johnson and Novartis, which were also in the fray to buy Paras and had submitted their bids to Actis.
Other companies that were interested in the deal were personal-care products maker Emami Ltd, Taisho Pharmaceuticals, Pfizer, Merck, Abbott Laboratories and Bayer.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
